Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CellSource Co., Ltd. ( (JP:4880) ) just unveiled an announcement.
CellSource Co., Ltd. announced a change in its representative director, with Dr. Masayuki Yamakawa assuming the role of Representative Chairman of the Board. This change aims to capitalize on Dr. Yamakawa’s medical expertise to enhance the company’s strategic management and realize its ‘CellSource Vision’ for sustainable growth and increased corporate value.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the medical industry, focusing on regenerative medicine and related healthcare services. The company is known for its innovative approaches in medical treatments, leveraging expertise in cell-based therapies.
YTD Price Performance: -2.16%
Average Trading Volume: 100,191
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen15.97B
For a thorough assessment of 4880 stock, go to TipRanks’ Stock Analysis page.
